Open AccessPharmacological evaluation of novel 5-HT 3 receptor antagonist, QCM-13 (N-cyclohexyl-3-methoxyquinoxalin-2-carboxamide) as anti-anxiety agent in behavioral test battery
Author(s) -
Deepali Gupta,
Radhakrishnan Mahesh,
Thangaraj Devadoss,
Yeshwant Kurhe
Publication year - 2015
Publication title -
journal of pharmacy and bioallied sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.268
H-Index - 36
eISSN - 0976-4879
pISSN - 0975-7406
DOI - 10.4103/0975-7406.154429
Subject(s) - antagonist , anxiety , pharmacology , battery (electricity) , carboxamide , medicine , neuroscience , psychology , psychiatry , chemistry , receptor , stereochemistry , physics , power (physics) , quantum mechanics
In the last few decades, serotonin type-3 (5-HT3) receptor antagonists have been identified as potential targets for anxiety disorders. In preclinical studies, 5-HT3 antagonists have shown promising antianxiety effects. In this study, a novel 5-HT3 receptor antagonist, QCM-13(N-cyclohexyl-3-methoxyquinoxalin-2-carboxamide) was evaluated for anxiolytic-like activity in rodent behavioral test battery.